# US 2016/0354399 A1 · Substituted gemcitabine aryl amide analogs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354399 A1
- Document ID: US20160354399A1
- Status: Published application
- Kind: A1
- Application number: 15/231,310
- Filed: 2016-08-08
- Published: 2016-12-08
- Earliest claimed: 2012-11-07
- Assignees: Nucorion Pharmaceuticals, Inc.
- Applicants: Nucorion Pharmaceuticals, Inc.
- Inventors: Zucai Suo
- Web page: https://patentgrep.com/patent/US20160354399A1

## CPC

- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 31/282: Platinum compounds
- A61K 31/555: containing heavy metals, e.g. hemin, hematin, melarsoprol
- A61K 33/243: Platinum; Compounds thereof
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/10: of the bladder
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 31/20: for DNA viruses
- A61P 31/22: for herpes viruses
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07H 19/06: Pyrimidine radicals
- C07H 19/067: with ribosyl as the saccharide radical
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

In accordance with the purpose(s) of the invention, as embodied and broadly described herein, the invention, in one aspect, relates to substituted gemcitabine aryl amide analogs, methods of making the same, pharmaceutical compositions comprising same, methods of treating viral disorders and disorders of uncontrolled cellular proliferation using same.

## Claims

### Claim at position 1

-104. (canceled)

### Claim 105

A composition comprising: a compound, or pharmaceutically acceptable salt, solvate, or polymorph thereof, having a structure of formula (I):
wherein:
R1a and R1e are independently selected from hydrogen, fluoro, chloro, bromo, iodo, methyl, methoxy, fluoromethyl, fluoromethoxy, difluoromethyl, difluoromethoxy, trifluoromethyl, trifluoromethoxy, ethyl, ethoxy, propyl, propoxy, butyl, butoxy, cyano, hydroxy, thiol, alkylthiol, optionally substituted benzyl, optionally substituted phenoxy, nitro, amino, monoalkylamino, and dialkylamino;
R1b and R1d are independently selected from hydrogen, fluoro, chloro, bromo, iodo, methyl, methoxy, fluoromethyl, fluoromethoxy, difluoromethyl, difluoromethoxy, trifluoromethyl, trifluoromethoxy, ethyl, ethoxy, propyl, propoxy, butyl, butoxy, cyano, hydroxy, thiol, alkylthiol, optionally substituted phenyl, optionally substituted benzyl, optionally substituted phenoxy, nitro, amino, monoalkylamino, and dialkylamino;
R1c is selected from hydrogen, fluoro, chloro, bromo, iodo, methyl, methoxy, fluoromethyl, fluoromethoxy, difluoromethyl, difluoromethoxy, trifluoromethyl, trifluoromethoxy, ethyl, ethoxy, propyl, propoxy, butyl, butoxy, cyano, hydroxy, thiol, alkylthiol, optionally substituted phenyl, optionally substituted benzyl, optionally substituted phenoxy, —C(O)R5, —C(O)OR5, —C(O)NHR5, —OC(O)R5, —NHC(O)R5, and —NHC(O)OR5;
at least one of R1a, R1b, R1c, R1d, and R1e is not hydrogen;
R5 is hydrogen, methyl, ethyl, propyl, butyl, pentyl, or hexyl;
R2 is selected from hydrogen, C1-C4 alkyl, and amine protecting group;
R3 is selected from hydrogen and hydroxyl protecting group;
R4 is selected from hydrogen, C1-C8 alkyl, and hydroxyl protecting group;
or R3 and R4 together comprise a divalent moiety having a structure represented by a formula:
and
each R6 is independently selected from methyl, ethyl, propyl, and butyl; and
an additional therapeutic compound.

### Claim 106 (depends on 105)

The composition of claim 105, wherein the additional therapeutic compound is selected from an antiviral compound, and an inhibitor of uncontrolled cellular proliferation.

### Claim 107 (depends on 106)

The composition of claim 106, wherein the additional therapeutic compound is an antiviral compound.

### Claim 108 (depends on 107)

The composition of claim 107, wherein the antiviral compound is selected from the group consisting of:

### Claim 109 (depends on 106)

The composition of claim 106, wherein the additional therapeutic compound is an inhibitor of uncontrolled cellular proliferation.

### Claim 110 (depends on 109)

The composition of claim 109, wherein the inhibitor of uncontrolled cellular proliferation is carboplatin.

### Claim 111 (depends on 105)

The composition of claim 105, wherein at least two of R1a, R1b, R1c, R1d, and R1e are not hydrogen.

### Claim 112 (depends on 105)

The composition of claim 105, wherein R1a=R1e, and wherein R1b, R1c, and R1d are hydrogen.

### Claim 113 (depends on 105)

The composition of claim 105, wherein R1b=R1d, and wherein R1a, R1c, and R1e are hydrogen.

### Claim 114 (depends on 105)

The composition of claim 105, wherein R1b=R1c=R1d, and wherein R1a and R1e are hydrogen.

### Claim 115 (depends on 105)

The composition of claim 105, wherein R2 is an amine protecting group selected from the group consisting of Fmoc, BOC, Cbz, acetyl, trifluoroacetamide, phthalimide, benzyl, triphenylmethylamine, benzylideneamine, and p-toluenesulfonamide.

### Claim 116 (depends on 105)

The composition of claim 105, wherein R3 and R4 are independently a hydroxyl protecting group selected from the group consisting of MOM, THP, t-butyl ether, allyl ether, benzyl, TIPDS, TBDMS, TBDPS, acetyl, pivalic acid ester, acetonide, benzoyl, and benzylidene acetal.

### Claim 117 (depends on 105)

The composition of claim 105, wherein R3 and R4 together comprise a divalent moiety having a structure represented by a formula:

### Claim 118 (depends on 105)

The composition of claim 105, wherein R2, R3, and R4 are hydrogen.

### Claim 119 (depends on 105)

The composition of claim 105, wherein either R1a and R1e, or R1b and R1d are independently selected from methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, butoxy, fluoromethyl, fluoromethoxy, difluoromethyl, difluoromethoxy, trifluoromethyl, and trifluoromethoxy.

### Claim 120 (depends on 105)

The composition of claim 105, wherein either R1a and R1e, or R1b and R1d are selected from cyano, hydroxy, thiol, alkylthiol, optionally substituted benzyl, optionally substituted phenoxy, nitro, amino, monoalkylamino, and dialkylamino

### Claim 121 (depends on 105)

The composition of claim 105, wherein either R1a and R1e, or R1b and R1d are selected from fluoro, chloro, bromo, iodo, and methoxy.

### Claim 122 (depends on 105)

The composition of claim 105, wherein R1c is selected from methyl, ethyl, propyl, butyl, methoxy, ethoxy, propoxy, butoxy. fluoromethyl, fluoromethoxy, difluoromethyl, difluoromethoxy, trifluoromethyl, and trifluoromethoxy.

### Claim 123 (depends on 105)

The composition of claim 105, wherein R1c is selected from cyano, hydroxy, thiol, alkylthiol, optionally substituted phenyl, optionally substituted benzyl, optionally substituted phenoxy, —C(O)R5, —C(O)OR5, —C(O)NHR5, —OC(O)R5, —NHC(O)R5, and —NHC(O)OR5.

### Claim 124 (depends on 105)

The composition of claim 105, wherein R1c is selected from fluoro, chloro, bromo, iodo, and methoxy.

### Claim 125 (depends on 105)

The composition of claim 105,
wherein two or three of R1a, R1b, R1c, R1d, and R1e are not hydrogen;
each of R1a, R1b, R1c, R1d, and R1e is independently selected from hydrogen, chloro, and methoxy; and
R2, R3, and R4 are hydrogen.

### Claim 126 (depends on 125)

The composition of claim 125, wherein R1a=R1e≠H, or R1b=R1d≠H, or R1a=R1c=R1e≠H, or R1b=R1c=R1d≠H.

### Claim 127 (depends on 105)

The composition of claim 105, wherein formula (I) is selected from the group consisting of:

### Claim 128 (depends on 105)

A pharmaceutical composition comprising the composition of claim 105 and a pharmaceutically acceptable carrier.

### Claim 129 (depends on 105)

A method for treating a subject having a disorder selected from a the group consisting of a viral infection and cancer, the method comprising administering to the subject in need thereof an effective amount of the composition of claim 105.

### Claim 130 (depends on 129)

The method of claim 129, wherein the additional therapeutic compound is selected from an antiviral compound and an inhibitor of uncontrolled cellular proliferation.

### Claim 131 (depends on 130)

The method of claim 130, wherein the antiviral compound is selected from the group consisting of:

### Claim 132 (depends on 130)

The method of claim 130, wherein the inhibitor of uncontrolled cellular proliferation is carboplatin.

### Claim 133 (depends on 129)

The method of claim 129, wherein the viral infection comprises a virus selected from the group consisting of dengue virus, Human immunodeficiency virus, Hepatitis A, Hepatitis B, Hepatitis C, Herpes simplex, Cytomegalovirus, Epstein-Barr virus, and Yellow fever virus.

### Claim 134 (depends on 129)

The method of claim 129, wherein the cancer is selected from the group consisting of non-small cell lung cancer, pancreatic cancer, bladder cancer, esophageal cancer, lymphoma, and breast cancer.
